CTLA4 and neoplasm: In a study conducted on murine pancreatic cancer, blocking the colony-stimulating factor-1 receptor to deplete macrophages led to substantial tumor regression when combined with PD-1 and CTLA-4 blockade, which otherwise had no significant anti-tumor effects, indicating the role of TAMs in the therapeutic effects of ICB (79).